CION Ameerpet
After brain tumour treatment, the scan that matters most is the next one. Surveillance MRI watches for regrowth — often before you would ever feel it. We read every scan against your own history, so a real change is spotted, not missed.
Once your treatment is over — surgery, radiation, or chemotherapy — the goal shifts to watching. A surveillance MRI (also called a follow-up or monitoring scan) is a brain MRI done at planned intervals to check whether the tumour stays controlled or shows any sign of regrowth. It is the single most useful tool for finding a recurrence early.
These scans are not the same as the MRI used to first diagnose a tumour. Surveillance scans are about comparison over time. Each new image is read alongside your previous ones, so even a small change stands out. If you want a refresher on how brain MRI works, see our page on the MRI for a brain tumour, and our main brain tumour treatment in Hyderabad page for the full care pathway.
For glioblastoma and other high-grade gliomas, NCCN guidelines recommend a follow-up brain MRI roughly every 2 to 3 months for the first 2–3 years after treatment, then less often if scans remain stable. The schedule is deliberately most intensive in the early period, because this is when recurrence is most likely. Source: NCCN Clinical Practice Guidelines in Oncology — Central Nervous System Cancers.
It is natural to want to put scans behind you once treatment ends. But many brain tumours can begin to regrow silently, with no symptoms at all for months. A surveillance MRI is designed to catch that change before it causes a headache, a seizure, or new weakness.
Wondering whether a tumour can return at all? Our page Can a brain tumour come back after removal? explains recurrence in plain language. To set up or review a monitoring schedule, talk to a CION neuro-oncologist.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Due a follow-up scan, unsure of your schedule, or treated elsewhere and want monitoring closer to home? CION's neuro-oncology team can set up and read your surveillance MRIs.
There is no single answer — the right interval depends on your tumour type, WHO grade, and how your treatment went. The schedule is most intensive in the first few years, then usually relaxes if scans stay stable. The ranges below reflect NCCN and EANO guidance and are a starting point your team will personalise.
| Tumour situation | Typical early interval | Later (if stable) |
|---|---|---|
| High-grade glioma / glioblastoma | Every 2–3 months for 2–3 years | Every 3–6 months |
| Low-grade (Grade 2) glioma | Every 3–6 months | Every 6–12 months |
| Fully removed benign tumour (e.g. many meningiomas) | At 3–6 months, then yearly | Yearly, then less often |
| Treated brain metastases | Every 2–3 months | Guided by systemic disease status |
Intervals are indicative and reviewed at every visit — they can shorten if a scan is uncertain or lengthen once things settle. Always follow the schedule your own neuro-oncology team sets.
A surveillance MRI is usually done with gadolinium contrast, which highlights active or regrowing tumour tissue that a plain scan can miss. Reading the scan is mostly about comparison — your radiologist and oncologist look for:
When a finding is hard to interpret, the team may add advanced sequences — perfusion MRI (which assesses blood flow within a suspicious area) and MR spectroscopy (which looks at its chemical signature) — to help tell true tumour from treatment change. Tell the team beforehand about any allergy, kidney problem, or pregnancy so contrast can be planned safely.
One of the most important reasons surveillance MRI should be read by a team experienced with treated brain tumours is a phenomenon called pseudoprogression. After chemoradiation for glioblastoma — particularly in MGMT-methylated tumours — the first scans can show what looks like new or growing enhancement that is actually treatment-related inflammation, not real tumour growth.
Mistaking pseudoprogression for true recurrence can lead to stopping a treatment that is in fact working. Experienced neuro-oncologists recognise the pattern, often repeat the MRI in a few weeks, and use advanced sequences to clarify. A related effect, radiation necrosis, can appear months to years later and is also managed without assuming the worst. EANO and NCCN both stress reading these scans in context — against prior imaging and the clinical picture — rather than from a single image.
Pseudoprogression can affect a meaningful share of glioblastoma patients in the first 3 months after chemoradiation, and it is more common in tumours with MGMT promoter methylation — the same feature that predicts a better response to temozolomide. This is why a single early scan is rarely acted on alone. Source: EANO guidelines on the diagnosis and treatment of diffuse gliomas.
A change on a surveillance MRI does not automatically mean the tumour is back. There is a careful, step-by-step process before anyone concludes anything:
CION delivers the radiation, systemic (medical) therapy, imaging, molecular testing, and supportive care directly. Any neurosurgery is coordinated with accredited neurosurgical partners — never assumed without confirmation.
A second opinion on monitoring is especially worthwhile if any of the following apply:
You can see CION even if your surgery or radiation was at another hospital — bring your prior MRIs, surgery and pathology reports, and molecular results (IDH, MGMT, 1p/19q). Our team can also point you to the right brain cancer doctors in Hyderabad for ongoing care, and the broader brain cancer and tumour hub covers diagnosis and treatment in depth. To have your plan reviewed, request a free second opinion or call 18002028726.
Get a free written second opinion from CION's neuro-oncology tumour board — particularly useful if an early scan was uncertain or no clear monitoring plan was set.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.The schedule depends on your tumour type and grade. After treatment for a high-grade glioma such as glioblastoma, NCCN guidance suggests an MRI roughly every 2 to 3 months for the first 2–3 years, then less often if scans stay stable. For a low-grade glioma or a fully removed benign tumour, intervals are usually longer — every 3 to 6 months at first, stretching to yearly over time. Your neuro-oncology team sets a personalised plan based on your pathology, surgery, and how you are recovering. The interval is reviewed at every visit, so it can shorten if a scan is uncertain or lengthen once things are settled.
Surveillance MRI is designed to catch a recurrence before it causes symptoms. Many brain tumours can start to regrow silently — a small change on a scan is often visible months before you would notice a headache, seizure, or weakness. Finding regrowth early usually means more treatment options and easier decisions. Feeling well is reassuring, but it does not replace imaging. At CION, the scan plus your clinical review together guide each step. If a scan is clear and you feel well, that is the best possible result — and a reason to continue the schedule, not stop it.
Pseudoprogression is treatment-related inflammation that can make an early post-radiation scan look worse than the tumour really is. It is common in the first 3 months after chemoradiation for glioblastoma — especially in MGMT-methylated tumours. Mistaking it for true regrowth can lead to stopping a working treatment too soon. Experienced neuro-oncologists recognise this pattern, often repeat the scan in a few weeks, and may add advanced sequences (perfusion or spectroscopy) to tell inflammation from real growth. This is one of the strongest reasons surveillance MRI should be read by a team familiar with treated brain tumours.
Most follow-up scans for a treated brain tumour use gadolinium contrast, because contrast highlights active or regrowing tumour tissue that a plain scan can miss. Your team compares each contrast-enhanced scan with your previous ones to spot subtle change. Some stable, long-term patients may move to less frequent contrast use, and anyone with kidney concerns or a contrast reaction history is assessed individually first. You do not decide this alone — the radiologist and your oncologist choose the right sequences for each visit. Tell the team about any allergy, kidney problem, or pregnancy before the scan so it can be planned safely.
A change does not automatically mean the tumour is back. The first step is review by the multidisciplinary tumour board, comparing the new images with earlier scans. Options include a short-interval repeat MRI, advanced MRI sequences, or — if needed — a biopsy coordinated with our neurosurgical partners to confirm what the change is. Only then is a plan made. If recurrence is confirmed, treatment is tailored to the type and location and may involve further radiation, systemic therapy, or surgery coordinated with accredited neurosurgical partners. You can read more about how a tumour may return on our page Can a brain tumour come back after removal?
Yes. Many patients come to CION for ongoing monitoring after surgery or radiation at another hospital. Bring your previous MRIs, your surgery and pathology reports, and any molecular test results (IDH, MGMT, 1p/19q). Comparing new scans with your baseline is essential, so older images are valuable — request copies on disc or via your prior centre. Our neuro-oncology team will set up a surveillance schedule, read each scan against your history, and coordinate any next steps. A free written second opinion is available if you would like your current monitoring plan reviewed.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.